Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 39

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity

Ahmad, Jawad, Odin, Joseph A. · 2017 · Clinics in Liver Disease

Abstract

Idiosyncratic DILI from prescription medications and herbal and dietary supplements has an annual incidence rate of approximately 20 cases per 100,000 per year. However, the risk of DILI varies greatly according to the drug. In the US and Europe antimicrobials are the commonest implicated agents, with amoxicillin/clavulanate the most common, while in Asian countries herbal and dietary supplements predominate. Several demographic factors are associated with the risk of DILI as well as the severity and outcome. Genetic analysis of DILI is currently limited but multiple polymorphisms of HLA genes and genes involved in drug metabolism and transport have been identified as risk factors for DILI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cld.2016.08.004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 69

  1. Zhang, 2012, Pharmacogenetics of drugs withdrawn from the market, Pharmacogenomics, 13, 223, 10.2217/pgs.11.137 · DOI
  2. Sgro, 2002, Incidence of drug-induced hepatic injuries: a French population-based study, Hepatology, 36, 451, 10.1053/jhep.2002.34857 · DOI · Paper page
  3. Suk, 2012, A prospective nationwide study of drug-induced liver injury in Korea, Am J Gastroenterol, 107, 1380, 10.1038/ajg.2012.138 · DOI · Paper page
  4. de Abajo, 2004, Acute and clinically relevant drug-induced liver injury: a population based case-control study, Br J Clin Pharmacol, 58, 71, 10.1111/j.1365-2125.2004.02133.x · DOI · Paper page
  5. Ruigómez, 2014, Ascertainment of acute liver injury in two European primary care databases, Eur J Clin Pharmacol, 70, 1227, 10.1007/s00228-014-1721-y · DOI
  6. De Valle, 2006, Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic, Aliment Pharmacol Ther, 24, 1187, 10.1111/j.1365-2036.2006.03117.x · DOI · Paper page
  7. Chalasani, 2015, Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study, Gastroenterology, 148, 1340, 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  8. Andrade, 2005, Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period, Gastroenterology, 129, 512, 10.1016/j.gastro.2005.05.006 · DOI · Paper page
  9. Takikawa, 2009, Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006, Hepatol Res, 39, 427, 10.1111/j.1872-034X.2008.00486.x · DOI · Paper page
  10. Wai, 2006, Presentation of drug-induced liver injury in Singapore, Singapore Med J, 47, 116
  11. Bessone, 2016, The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative, Int J Mol Sci, 17, 313, 10.3390/ijms17030313 · DOI
  12. Björnsson, 2012, Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing, J Hepatol, 56, 374, 10.1016/j.jhep.2011.07.023 · DOI · Paper page
  13. Charles, 2005, Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization, Am J Med, 118, 618, 10.1016/j.amjmed.2005.02.008 · DOI
  14. Robles-Diaz, 2015, Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids, Aliment Pharmacol Ther, 41, 116, 10.1111/apt.13023 · DOI · Paper page
  15. Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
  16. Hunt, 2014, Age-related differences in reporting of drug-associated liver injury: data-mining of WHO safety report database, Regul Toxicol Pharmacol, 70, 519, 10.1016/j.yrtph.2014.09.007 · DOI
  17. Molleston, 2011, Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study, J Pediatr Gastroenterol Nutr, 53, 182, 10.1097/MPG.0b013e31821d6cfd · DOI
  18. Murray, 2008, Drug-related hepatotoxicity and acute liver failure, J Pediatr Gastroenterol Nutr, 47, 395, 10.1097/MPG.0b013e3181709464 · DOI
  19. Fontana, 2014, Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset, Gastroenterology, 147, 96, 10.1053/j.gastro.2014.03.045 · DOI · Paper page
  20. Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
  21. Vuppalanchi, 2014, Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome, Clin Gastroenterol Hepatol, 12, 1550, 10.1016/j.cgh.2013.12.016 · DOI
  22. Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI · Paper page
  23. Meier, 2005, Incidence of drug-induced liver injury in medical inpatients, Eur J Clin Pharmacol, 61, 135, 10.1007/s00228-004-0888-z · DOI · Paper page
  24. Chalasani, 2004, Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity, Gastroenterology, 126, 1287, 10.1053/j.gastro.2004.02.015 · DOI · Paper page
  25. Lewis, 2007, Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial, Hepatology, 46, 1453, 10.1002/hep.21848 · DOI · Paper page
  26. Wong, 2000, Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection, Hepatology, 31, 201, 10.1002/hep.510310129 · DOI · Paper page
  27. Lee, 2005, Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy, Chest, 127, 1304
  28. den Brinker, 2000, Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection, AIDS, 14, 2895, 10.1097/00002030-200012220-00011 · DOI · Paper page
  29. Sulkowski, 2002, Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections, Hepatology, 35, 182, 10.1053/jhep.2002.30319 · DOI · Paper page
  30. Kramer, 2005, Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era, J Hepatol, 42, 309, 10.1016/j.jhep.2004.11.017 · DOI
  31. Kalow, 1987, Genetic variation in the human hepatic cytochrome P-450 system, Eur J Clin Pharmacol, 31, 633, 10.1007/BF00541288 · DOI
  32. Huang, 2002, Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis, Hepatology, 35, 883, 10.1053/jhep.2002.32102 · DOI · Paper page
  33. Sharma, 2014, Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity, Int J Tuberc Lung Dis, 18, 588, 10.5588/ijtld.13.0344 · doi:10.5588/ijtld.13.0344
  34. Gupta, 2013, Association of GST null genotypes with anti-tuberculosis drug induced hepatotoxicity in Western Indian population, Ann Hepatol, 12, 959, 10.1016/S1665-2681(19)31302-X · DOI
  35. Chatterjee, 2010, GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs, J Clin Pharm Ther, 35, 465, 10.1111/j.1365-2710.2009.01101.x · DOI
  36. Huang, 2003, Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis, Hepatology, 37, 924, 10.1053/jhep.2003.50144 · DOI · Paper page
  37. Bose, 2011, Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis, J Gastroenterol Hepatol, 26, 312, 10.1111/j.1440-1746.2010.06355.x · DOI
  38. An, 2012, NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients, Clin Exp Pharmacol Physiol, 39, 535, 10.1111/j.1440-1681.2012.05713.x · DOI
  39. Lee, 2010, NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis, Int J Tuberc Lung Dis, 14, 622
  40. Wang, 2012, NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis, Int J Tuberc Lung Dis, 16, 589, 10.5588/ijtld.11.0377 · DOI
  41. Chen, 2015, Association of polymorphisms in drug transporter genes (SLCO1B1 and SLC10A1) and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort, Tuberculosis (Edinb), 95, 68, 10.1016/j.tube.2014.11.004 · DOI
  42. Nanashima, 2012, Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients, Tuberculosis (Edinb), 92, 253, 10.1016/j.tube.2011.12.004 · DOI
  43. Chang, 2012, UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-tuberculosis medications, Int J Tuberc Lung Dis, 16, 376, 10.5588/ijtld.11.0404 · DOI
  44. Zazuli, 2015, Polymorphism of PXR gene associated with the increased risk of drug-induced liver injury in Indonesian pulmonary tuberculosis patients, J Clin Pharm Ther, 40, 680, 10.1111/jcpt.12325 · doi:10.1111/jcpt.12325
  45. Gao, 2012, HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients, AIDS Res Hum Retroviruses, 28, 540, 10.1089/aid.2011.0107 · doi:10.1089/aid.2011.0107
  46. Phillips, 2013, Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa, J Acquir Immune Defic Syndr, 62, e55, 10.1097/QAI.0b013e31827ca50f · doi:10.1097/qai.0b013e31827ca50f
  47. Carr, 2013, Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population, Clin Infect Dis, 56, 1330, 10.1093/cid/cit021 · DOI
  48. Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J Clin Oncol, 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
  49. Spraggs, 2012, Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes, Clin Pharmacol Ther, 91, 647, 10.1038/clpt.2011.277 · DOI
  50. Schaid, 2014, Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury, J Clin Oncol, 32, 2296, 10.1200/JCO.2013.52.9867 · DOI
  51. Hirata, 2008, Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study, Pharmacogenomics J, 8, 29, 10.1038/sj.tpj.6500442 · DOI · Paper page
  52. Cornejo Castro, 2015, HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysis, Pharmacogenet Genomics, 25, 186, 10.1097/FPC.0000000000000124 · DOI
  53. Samara, 2014, Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients, Int J Clin Pharmacol Ther, 52, 746, 10.5414/CP202098 · doi:10.5414/cp202098
  54. Adam de Beaumais, 2011, Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy, Br J Clin Pharmacol, 71, 575, 10.1111/j.1365-2125.2010.03867.x · doi:10.1111/j.1365-2125.2010.03867.x
  55. Karathanasis, 2011, The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia, Genet Test Mol Biomarkers, 15, 5, 10.1089/gtmb.2010.0083 · doi:10.1089/gtmb.2010.0083
  56. Mazor, 2013, Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease, Curr Drug Saf, 8, 181, 10.2174/15748863113089990033 · doi:10.2174/15748863113089990033
  57. Agúndez, 2011, Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity, Expert Opin Drug Metab Toxicol, 7, 817, 10.1517/17425255.2011.574613 · DOI
  58. Lucena, 2008, Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury, Hepatology, 48, 588, 10.1002/hep.22370 · DOI · Paper page
  59. Jiang, 2015, Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population, Pharmacogenomics J, 15, 326, 10.1038/tpj.2014.75 · DOI
  60. Ulzurrun, 2014, Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort, PLoS One, 9, e94675, 10.1371/journal.pone.0094675 · DOI
  61. Horinouchi, 2010, Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma, Pediatr Hematol Oncol, 27, 344, 10.3109/08880011003739422 · doi:10.3109/08880011003739422
  62. Nicoletti, 2016, HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury, Pharmacogenet Genomics, 26, 218, 10.1097/FPC.0000000000000209 · DOI
  63. Parham, 2016, Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01, Pharmacogenomics J, 16, 180, 10.1038/tpj.2015.40 · DOI
  64. Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
  65. Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379 · DOI · Paper page
  66. Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632 · DOI · Paper page
  67. Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458 · DOI · Paper page
  68. Urban, 2012, Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs, Pharmacogenet Genomics, 22, 784, 10.1097/FPC.0b013e3283589a76 · DOI
  69. Yip, 2015, Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review, Clin Rev Allergy Immunol, 48, 165, 10.1007/s12016-014-8418-y · DOI

Cited by

See all 39

Metadata

Authors
Ahmad, J., & Odin, J. A.
Venue
Clinics in Liver Disease
Publisher
Elsevier BV
Published
2017-02
Volume
21
Issue
1
Pages
55-72
ISSN
1089-3261
Cited by
39
References
4
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.